Bradycardia-tachycardia syndrome usually reflects the presence of sinoatrial disease, in which episodes of supraventricular tachycardia complicate sinus bradycardia with or without periods of sinus arrest or sinoatrial block.
Dizziness, syncope, or convulsions may result from cerebral ischaemia secondary to bradycardia, and tachycardia may cause palpitation, ischaemic cardiac pain, dyspnoea, and, more rarely, hypotension and cardiac failure. Systemic emboli may occur particularly in patients over 50 years (Rubenstein et al., 1972; Ferrer, 1973) .
The aetiology of the sick sinus syndrome and the bradycardia-tachycardia syndrome is often unknown, but associations with coronary artery disease, thyrotoxicosis, cardiomyopathy, amyloidosis, diabetes, and cardiac surgery have been reported, and there is a rare familial form (British Medical Journal, 1977 A woman aged 47 years was first seen in 1970 with paroxysmal supraventricular tachycardia occurring particularly at night. The patient reported pulse rates at under 40 a minute on other occasions. She was treated unsuccessfully with courses of propranolol, phenytoin, and procainamide, and periods of sinus bradycardia were seen to be associated with exhaustion and feelings of faintness. In January 1977, her blood pressure was 125/80 and a 24-hour electrocardiogram showed periods of sinus tachycardia at 130 a minute alternating with sinus bradycardia at 32 a minute and sinus arrest. She was started on amiodarone 200 mg twice daily, with no improvement, but on 200 mg three times per day she had no cardiac symptoms, and a repeat 24-hour electrocardiogram showed sinus rhythm varying between 60 and 84 beats a minute. She complained of feeling unwell without specific features, and blood pressure rose to 190/125 mmHg. Amiodarone was stopped after 10 weeks but the blood pressure remained high, and she has been on hypotensive agents since. The palpitation and exhaustion associated with bradycardia have persisted, and she is awaiting permanent cardiac pacemaking.
Discussion
Amiodarone is a benzofuran derivative which was originally introduced as an antianginal agent, but has subsequently been shown to be valuable in the management of atrial and ventricular arrhythmias and in the Wolff-Parkinson-White syndrome (Rosenbaum et al., 1976) . There have been no previous reports of the use of amiodarone in the bradycardia-tachycardia syndrome.
The principal actions of amiodarone are to cause relaxation of vascular smooth muscle resulting in a slight fall in systemic vascular resistance with slight reduction in systemic blood pressure, and a fall in coronary arterial resistance and improved coronary blood flow. The drug also causes an atropineresistant bradycardia, and reduces the effects of catecholamines and sympathetic stimulation without acting as a competitive cx and fi receptor blocking agent. Singh and Vaughan Williams (1970) report that amiodarone causes prolongation of the duration of the action potential in atrial and ventricular muscle with no change in the resting potential, and amiodarone has been grouped with bretylium as a class 3 antiarrhythmic agent (Olsson et al., 1973; Singh and Hauswirth, 1974 (ChArlier et al., 1972) . There is ample evidence of the efficacy of amiodarone in the management of arrhythmias, particularly of supraventricular origin (Van Schepdael and Solvay, 1975; Rosenbaum et al., 1976) , but its use has been limited because of concern over side effects. Bradycardia, thyroid disorders, skin lesions, photosensitivity, and one case of sensory ataxic paraesthesiae and tremor have been described (Lustman and Monsea, 1974) , but most concern has centred on the frequency of corneal micro deposits. The deposits, however, are usually found below the pupil, do not interfere with vision, are reversible, and may be prevented by methylcellulose eye drops (Francois, 1969; Soussi and Colonna, 1974) .
One patient, case 1, has developed corneal micro deposits without interference with vision, and 2 patients have stopped amiodarone. Case 3 has remained well after 6 weeks on the drug and 1 patient, case 5, felt generally unwell on amiodarone and her blood pressure rose significantly, so the drug was withdrawn after 10 weeks. In view of the usual hypotensive effect of amiodarone, the rise in blood pressure in this patient is surprising and unexplained, but may be a coincidental finding and not a true complication of therapy.
The most important finding in these 5 patients is that none of them developed symptomatic bradycardia despite taking adequate amiodarone to prevent supraventricular tachycardia. Failure of the drug to produce excessive slowing of the heart may reflect improved coronary arterial blood supply because of amiodarone-induced relaxation of smooth muscle in the coronary arteries. The sinus node is supplied by a single vessel arising from either the right coronary artery or the left circumflex artery, and improved blood flow through the sinus node artery as a result of amiodarone administration may improve perfusion of the sinus node, and the atrial myocardium and interatrial septum which receive blood supply via the same vessel. In 3 of the 5 patients in this series, ischaemic heart disease is the probable cause of the bradycardia-tachycardia syndrome and improved coronary arterial blood flow by amiodarone could aid atrial bradycardia in these patients.
We suggest that amiodarone deserves a trial in patients suffering from the bradycardia-tachycardia A. K. Brown, R. A. Primhak, and P. Newton syndrome before they are committed to permanent cardiac pacemaking.
